Veterinary Medicines Directorate

Woodham Lane, New Haw, Addlestone, Surrey KT15 3LS
Telephone +44 (0)1932 336911

Post Authorisation Assessments

Equest Oral Gel 18.92mg/g Oral Gel for Horse and Ponies

Vm 42058/5142

18 February 2025	One-off alignment of the product information with version v3 of the QRD templates.
22 December 2024	Extension of a re-test period/storage period supported by real time data.
26 May 2023	Changes in the composition (excipients) of the finished product.
26 May 2023	Change in name of the active substance or of an excipient. Change in name of the active substance or of an excipient.
26 May 2023	Change in name of the active substance or of an excipient. Change in name of the active substance or of an excipient.
10 January 2020	Change in the address of the marketing authorisation holder from Zoetis UK Limited, 5th Floor, 6 St. Andrew Street, London, EC4A 3AE to Zoetis UK Limited, 1st Floor, Birchwood Building, Springfield Drive, Leatherhead, Surrey, KT22 7LP.
05 March 2019	Changes (Safety/Efficacy) to Human and Veterinary Medicinal Products - Instructions for using dosing device updated.
07 November 2018	Change in the contact details of the QPPV of an existing pharmacovigilance system as described in the DDPS.
14 February 2018	Changes to the SPC/product labelling/package leaflet following an Article 35 referral.
09 November 2017	Submission of an updated Ph. Eur. certificate of suitability for an active substance from an already approved manufacturer.
07 October 2016	Mock-ups approved.
05 June 2015	Change in the QPPV and/or QPPV contact details and/or back-up procedure
04 July 2014	Submission of an updated Ph. Eur. Certificate of Suitability.
30 October 2013	Changes to an existing pharmacovigilance system and change to the name of a manufacturer responsible for the finished product and batch release.
24 October 2013	Change to the name of the MAH in France only.
31 July 2013	Transfer of MA from Pfizer Ltd to Zoetis UK Limited and change of distributor.
20 March 2013	Change in pack size of the finished product. Change in specification parameters and/or limits of

	finished product. Change in the batch size of the finished product Change in test procedure for the finished product Change in supplier of packaging components Change in shape/dimensions of the container or closure system.
13 June 2012	Introduction of a new pharmacovigilance system
21 February 2012	Approval of a new presentation: a box with 20 syringes.
04 November 2011	Change in name/address of a manufacturer of the finished product.
02 September 2011	Submission of a new Ph. Eur. Certificate of Suitability for an active substance from an already approved manufacturer
16 June 2010	Change of MAH
09 February 2009	Change of specification of the active substance to comply with Ph. Eur.
29 February 2008	Change in composition of immediate packaging
26 September 2007	Renewal
27 February 2007	Change of colour scheme of primary packaging
18 July 2006	Change of legal category from PML to POM-VPS Updates to the Product Literature
21 April 2004	Change of dosing device (larger syringe)
04 July 2003	Renewal Addition of an efficacy claim
07 March 2003	Change of manufacturing process of the active substance
04 September 2001	Change of starting materials used in the manufacture of the active substance
16 May 2001	Addition of an efficacy claim
18 May 2000	Change of shelf life from 18 months to 24 months
23 December 1999	Addition of a manufacturing site of the active substance
22 November 1999	Change of size of sterile containers
04 August 1999	Change of shelf life